1 / 18

Long term thérapy for PE of VTE

Long term thérapy for PE of VTE. C Becattini for the WARFASA study. Randomisée TVP sans cause retrouvée De 6 à 18 mois de TTT.

ima
Télécharger la présentation

Long term thérapy for PE of VTE

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Long term thérapy for PE of VTE

  2. C Becattini for the WARFASA study Randomisée TVP sans cause retrouvée De 6 à 18 mois de TTT

  3. Venous thromboembolism recurred in 28 of the 205 patients who received aspirin and in 43 of the 197 patients who received placebo (6.6% vs. 11.2% per year; hazard ratio, 0.58; 95% confidence interval [CI], 0.36 to 0.93)

  4. Schulman S et al RE-Medy and Re-Sonate trials Dabigatran 150 mg*2, Warfarine, Placébo Patient 3 mois après traitement initial pour VTE Randomisation 1/1 Dabigatran vs Placébo Randomisation 1/1 Dabigatran vs Warfarine (double insu; INR fictif) Recrutement spontané ou à partir des études RECOVER et RECOVER II Echo Doppler à 72 h de la rando Critères de jugement: Récidive clinique, saignements 2013;368:709-18

  5. Any bleeding at 1 year: Dabigatran 15%; Warfarin 20% Major Bleeding: Dabigatran: 5,6% Warfarin: 10,2%

  6. Apixaban 2,5 ou 5mg (2 XJ) vs placébo Randomisée en 1/1/1 Récurrence clinique de TVP ou EP Bleeding: Hb baisse de 2g/l ou transfusion Prétraitement par AC 6 à 12 mois 8 dec 2012

  7. Major Bleeding at 1 year: Apixaban 2,5*2 : 3%

  8. TVP ou EP sans facteur de risque majeur • Récidive de TVP ou EP peut être estimée à 10% par an lors des premières années • Effet positif de l’aspirine sur la récidive de TVP • Dabigatran à 150 mg*2 non inférieur à Warfarine. Taux moyen de récidive: 1% à 12 mois. • Effet significatif de l’apixaban 2,5 X 2 , sans sur-risque de saignement majeur. • Durée du Traitement ???

More Related